SPY320.07+8.71 2.80%
DIA272.21+8.88 3.37%
IXIC9,821.17+205.36 2.14%

SVB Leerink Maintains Outperform on Eidos Therapeutics, Lowers Price Target to $59

SVB Leerink maintains Eidos Therapeutics (NASDAQ:EIDX) with a Outperform and lowers the price target from $62 to $59.

Benzinga · 05/11/2020 10:27

SVB Leerink maintains Eidos Therapeutics (NASDAQ:EIDX) with a Outperform and lowers the price target from $62 to $59.